Fertility Decoded

Endometrial receptivity test (ERA)

A biopsy that claims to find your personal 'window' for embryo transfer.

Written by Fertility Decoded. Reviewed by D R, MS (OBG), FRM. Review date: 31 August 2026.

The verdict

Not shown to improve your chance of a baby.

Who are these bodies?

HFEA
— UK fertility regulator; rates add-ons by evidence (traffic-light).
ESHRE
— European fertility society; evidence-based practice guidance.
NICE
— UK health-guidance body; what the NHS will and won't fund.
ISAR
— Indian Society for Assisted Reproduction; Indian expert consensus.
Cochrane
— Independent global reviewers of the underlying studies.

  • HFEA

    UK regulator

    Red — may reduce effectiveness — chance of a baby
    Source

  • ESHRE

    European society

    Not recommended

    Not recommended for any patient group.

    Source

  • NICE

    UK NHS guidance

    Do not offer (2026)

    NG257 1.41.1: do not offer endometrial receptivity testing as a treatment add-on (includes gene-expression arrays like ERA).

    Source

  • ISAR

    Indian society

    No position

    Not addressed in the 2021 ISAR add-ons consensus.

  • Cochrane

    Evidence base

    RCTs show no improvement in live birth from timing transfers this way.

Typical cost in India

~₹35,000–55,000, plus a delayed/extra frozen cycle.

Should I have an ERA test?
The evidence does not support it. HFEA rates it red, NICE says do not offer it (2026), and randomised trials show no improvement in live birth from timing transfers this way.

Sources

Take this further

Sources last reviewed .